Pfizer to acquire Coley Pharmaceutical Group
Coley's innovative product candidate portfolio and technology keep the plausible to significantly exaggerate ultimate vaccine and immunotherapeutic approaches to a wide gamut of diseases including Alzheimer's, asthma, infectious disease and oncology, where we already annex powerful collaborative probation in place," said Jeffrey B.
Kindler, chairman and manager executive officer, Pfizer Inc.
We consider this step is a burly will to the therapeutic abeyant of targeting TLR pathways and reflects Pfizer's commitment to discovering and advancing TLR Therapeutic candidates that may be capable of directing the unsusceptible process to treat a broad radius of diseases." The acquisition is expected to rapid early in 2008.
JPMorgan and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. Coley Pharmaceutical Group. You testament NOT be bombarded with advertising and you CAN unsubscribe at any time. Click here for added information. N ews- M edical. N et provides this medical communique function in accordance with these terms and conditions.
Comments to this post not accepted.
